Related Experiment Video
Updated: Aug 24, 2026

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied
Tiina T Tuomisto1, Tuomas T Rissanen, Ismo Vajanto
1Department of Biotechnology and Molecular Medicine, A. I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland.
Abstract:
Critical lower limb ischemia is a common cause for amputation. To develop new therapeutic strategies, more information is needed about molecular mechanisms of tissue responses to ischemic stress and factors inducing angiogenesis. Using a DNA array of 8400 genes, gene expression patterns in human skeletal muscle samples collected from lower limbs amputated due to acute-on-chronic or chronic critical lower limb ischemia, were compared with the control samples collected from the same limb. The results were confirmed by RT-PCR and immunohistochemistry. In acute-on-chronic ischemia, 291 genes were significantly upregulated and 174 genes were downregulated (change in 5.5% of all genes) as compared to control samples. Significant induction of the hypoxia-inducible angiogenic pathway involving hypoxia-inducible factor-1alpha (HIF-1alpha), HIF-2alpha, vascular endothelial growth factor (VEGF) and its angiogenic receptor VEGFR-2, as well as tumor necrosis factor-alpha (TNF-alpha) with its downstream signaling machinery promoting inflammation and cell death, were found in acute-on-chronic ischemia. In chronic critical ischemia, gene expression changes were much less striking than in acute-on-chronic ischemia, with 74 genes significantly upregulated and 34 genes downregulated (change in 1.3% of all genes). In the chronic situation, the anabolic and survival factors, insulin-like growth factor-1 (IGF-1) and IGF-2, were upregulated in atrophic and regenerating myocytes together with attenuated HIF, VEGF, and VEGFR-2 expression in the same cells. In conclusion, acute-on-chronic and chronic human skeletal muscle ischemia result in distinct gene expression patterns. These findings may be of importance in the design of novel therapies, such as therapeutic vascular growth, for patients suffering from lower limb ischemia.
Insights
Critical lower limb ischemia leads to amputation. This study reveals distinct gene expression patterns in acute-on-chronic versus chronic ischemia, identifying pathways for potential therapeutic strategies like promoting vascular growth.
Area of Science:
- Molecular biology
- Genomics
- Vascular biology
Background:
- Critical lower limb ischemia is a major cause of amputation.
- Understanding molecular responses to ischemic stress and angiogenesis is crucial for developing new therapies.
Purpose of the Study:
- To compare gene expression patterns in human skeletal muscle from patients with acute-on-chronic or chronic critical lower limb ischemia versus control samples.
- To identify molecular mechanisms underlying tissue responses to different forms of ischemia and factors involved in angiogenesis.
Main Methods:
- DNA array analysis of 8400 genes in human skeletal muscle samples.
- Validation of gene expression changes using RT-PCR and immunohistochemistry.
- Comparison of gene expression between ischemic (acute-on-chronic, chronic) and control limb samples.
Main Results:
- Acute-on-chronic ischemia showed significant upregulation (291 genes) and downregulation (174 genes) of gene expression.
- This form of ischemia induced the hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, vascular endothelial growth factor (VEGF), VEGFR-2, and tumor necrosis factor-alpha (TNF-alpha) pathways.
- Chronic ischemia exhibited less pronounced gene expression changes (74 upregulated, 34 downregulated) with upregulation of insulin-like growth factors (IGF-1, IGF-2) and attenuated HIF/VEGF/VEGFR-2 signaling.
Conclusions:
- Acute-on-chronic and chronic critical lower limb ischemia present distinct molecular profiles in skeletal muscle.
- These findings offer insights into therapeutic targets for promoting vascular growth and treating lower limb ischemia.

